ConvaTec Advances ConvaVAC Ag+ Trial, Reinforcing Long-Term Wound Care Growth Story

ConvaTec Group plc (GB:CTEC) announced an update on their ongoing clinical study.

ConvaTec Group plc is preparing a new clinical study titled “A Study to Determine the Safety and Performance of ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds.” The trial aims to assess how safe and effective the ConvaVAC Ag+ system is for treating chronic venous leg ulcers, a common and costly wound type. For investors, this matters because better outcomes in these hard-to-heal wounds can support premium pricing, stronger adoption in hospitals and clinics, and a clearer growth story in advanced wound care.

The study tests a single device-based treatment: the ConvaVAC™ Ag+ Negative Pressure Wound Therapy System. It combines negative pressure (suction) with a silver-based component designed to help manage infection risk while promoting wound healing. The aim is to speed up closure of long-lasting leg ulcers, reduce complications, and potentially lower overall treatment costs.

The study is an interventional trial with one treatment group only, so all enrolled patients receive the ConvaVAC Ag+ therapy. There is no randomisation or placebo group. There is also no masking, meaning doctors and patients know which treatment is being used. The main goal is practical: to see how well the system works in real-world chronic wounds and whether it remains safe over the course of use.

The study was first submitted on 6 January 2026, indicating ConvaTec is still in the setup phase and the status is listed as “not yet recruiting.” The latest update was filed on 28 January 2026, showing the protocol is active and being refined. Primary completion and final completion dates are not yet specified, so meaningful clinical readouts are likely still some distance away. For investors, this suggests that any direct revenue impact will be medium to long term rather than immediate.

From a market perspective, this update reinforces ConvaTec’s push in advanced wound care, a segment where it competes with players such as Smith & Nephew and Mölnlycke. A well-executed study with clear safety and performance benefits could support higher market share in negative pressure wound therapy and strengthen ConvaTec’s negotiating position with payers and providers. Near term, the impact on the share price may be modest, as the trial is early stage and not yet recruiting, but it underpins the long-run growth narrative and may support investor confidence in the pipeline compared with peers that are slower to refresh their wound portfolios.

The study is currently in the setup phase and remains an active project, with ongoing updates available on the ClinicalTrials portal.